-+ 0.00%
-+ 0.00%
-+ 0.00%

Lakewood-Amedex wins IRB approval for Phase 2a Nu-3 diabetic foot ulcer trial

PUBT·09/18/2026 12:14:36
Listen to the news
Lakewood-Amedex wins IRB approval for Phase 2a Nu-3 diabetic foot ulcer trial
  • Lakewood-Amedex won central IRB clearance for its Phase 2a Nu-3 trial in mildly infected diabetic foot ulcers.
  • All participating sites also secured IRB sign-off, clearing the way to start patient enrollment.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lakewood-Amedex Biotherapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY51161) on September 18, 2026, and is solely responsible for the information contained therein.